These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15148985)

  • 41. Pharmaceuticals, the state and the global harmonisation process.
    Abraham J
    Aust Health Rev; 2004 Nov; 28(2):150-60. PubMed ID: 15527395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transparency of EU medicines agencies.
    Kopp C
    Prescrire Int; 2003 Aug; 12(66):156. PubMed ID: 12908499
    [No Abstract]   [Full Text] [Related]  

  • 44. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hybrid medicines in France. Hybrid medicines: Genesis and legal framework in Europe and in France].
    Leclerc E; Fusier I; Paubel P
    Ann Pharm Fr; 2021 Nov; 79(6):609-616. PubMed ID: 33961828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In that case: a pharmaceutical company that makes generic versions of commonly used drugs has produced a generic of a proprietary drug widely prescribed in a particular service. Response.
    Menkes DB; Woodall AA
    N Z Bioeth J; 2003 Oct; 4(3):22, 24-5. PubMed ID: 15597480
    [No Abstract]   [Full Text] [Related]  

  • 47. [Corrupt research may damage public health].
    Waldum HL
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2672-3. PubMed ID: 16215620
    [No Abstract]   [Full Text] [Related]  

  • 48. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 49. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 50. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
    Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
    Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
    [No Abstract]   [Full Text] [Related]  

  • 52. Will children with cancer benefit from the new European Paediatric Medicines Regulation?
    Vassal G
    Eur J Cancer; 2009 Jun; 45(9):1535-46. PubMed ID: 19419857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generics: what is the role of registration authorities.
    Versantvoort C; Maliepaard M; Lekkerkerker F
    Neth J Med; 2008 Feb; 66(2):62-6. PubMed ID: 18292608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The end of the beginning?
    Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702
    [No Abstract]   [Full Text] [Related]  

  • 56. Outsourcing lead optimization: constant change is here to stay.
    Clark DE
    Drug Discov Today; 2007 Jan; 12(1-2):62-70. PubMed ID: 17198974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Preselection procedure for medical devices suppliers at the essential medicines and generic drugs purchasing central in Togo (CAMEG-Togo)].
    Babaley M
    Med Trop (Mars); 2006 Dec; 66(6):623-30. PubMed ID: 17286037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmaceuticals: a strategic national industry].
    Hollender L
    Bull Acad Natl Med; 2004; 188(4):701-13. PubMed ID: 15587688
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of biogenerics: a survey of viewpoints.
    Nieminen O; Nordström K
    BioDrugs; 2004; 18(6):399-406. PubMed ID: 15571423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Doctors' dilemma paralyses French medicine.
    Butler D
    Nature; 1993 Jun; 363(6431):663. PubMed ID: 8515805
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.